Expanding Rapid Ascertainment Network of Schizophrenia Families in Taiwan

NCT01249079 | Unknown

• 1 other identifier: DMR99-IRB-214
• Study Type: observational
• Target: 600
• Locations: 1 country
• Sites: 1

Brief Summary

This proposal responds to Request for Applications RFA-MH-08-131, which seeks applications that propose to enrich pre-existing resources for schizophrenia in the National Institute of Mental Health (NIMH) Human Genetics Initiative and to apply genomic methods to further the investigators understanding of the molecular etiology of the disorder. The overarching aims of this proposal are to quickly and cost-effectively ascertain a large sample of trio families affected by schizophrenia, and to discover causal variants for the disorder in the first family-based genome-wide association study (GWAS) of the disorder. In Taiwan, there is no such kind of policy to support this kind of GWAS study as it is a very expensive study, including collecting large family samples and genome-wide single-nucleotide polymorphism (SNP) scanning. The investigators, thus, collaborate with Professor Ming T, Tsuang and his entended subcontracted researchers to apply for this project. The investigators, the research team in Taiwan, will collect 3800 trio families (11400 subjects) of schizophrenia. Through additional ascertainment within this framework, the investigators will collect an aggregate sample with adequate power for detecting in a GWAS those variants that make even small contributions to the risk for the disorder. The investigators will meet the overarching goals of this project by accomplishing several Specific Aims, as follows: 1) Rapidly ascertain schizophrenia trio families from Taiwanese clinical ascertainment sites; 2) Supplement NIMH Genetics Initiative collections by sending all clinical data and biomaterials to the appropriate repositories; 3) Assess the association of schizophrenia with a genome-wide panel of single-nucleotide polymorphisms (SNPs) and their constituent haplotypes; 4) Analyze quantitative schizophrenia phenotypes such as age at onset ; 5) Perform a genome-wide survey for copy-number variations related to schizophrenia; 6) Test for gene-gene interactions (epistasis); and 7) Test for gene-environment interactions, such as the well-established effect of season of birth.

Conditions

Schizophrenia

Study Arms (1)

Schizophrenia Family

Other: No intervention would be provided in this research

Interventions

No intervention would be provided in this research OTHER

No intervention would be provided in this research,but need to draw blood

Schizophrenia Family

Eligibility Criteria

• Age: 16 Years - 90 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Schizophrenia patients and their biological parents

You may qualify if:

• clinical diagnosis of schizophrenia and their parents, and parents are still alive

You may not qualify if:

• person with Mental Retardation
• persons with epilepsy
• alcohol or substance abuse combined
• in combination with other organic brain damage syndrome

Sponsors & Collaborators

• China Medical University Hospital: lead
• National Taiwan University Hospital: collaborator

Study Sites (1)

China Medical University Hospital

Taichung, Taiwan

RECRUITING

MeSH Terms

Conditions

Schizophrenia

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders

Study Officials

• Hsien-Yuan Lane

  China Medical University Hospital

  STUDY DIRECTOR

Central Study Contacts

Hai-Gwo Hwu

CONTACT

886-2-23122453; haigohwu@ntu.edu.tw

Study Design

• Study Type: observational
• Observational Model: FAMILY BASED
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: November 24, 2010
• First Posted: November 29, 2010
• Study Start: October 1, 2010
• Primary Completion: December 1, 2013
• Last Updated: December 1, 2010

Record last verified: 2010-10

Locations

TW (1)